The Goldman Sachs Group Begins Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Research analysts at The Goldman Sachs Group started coverage on shares of Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) in a research note issued to investors on Wednesday,Briefing.com Automated Import reports. The brokerage set a “neutral” rating and a $4.00 price target on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price points to […]
More Stories
MDA Space Ltd. (TSE:MDA) Director Michael Philip Greenley Sells 290,600 Shares
MDA Space Ltd. (TSE:MDA – Get Free Report) Director Michael Philip Greenley sold 290,600 shares of the company’s stock in...
Truist Financial Has Lowered Expectations for OrthoPediatrics (NASDAQ:KIDS) Stock Price
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) had its target price cut by research analysts at Truist Financial from $28.00 to...
Truist Financial Issues Positive Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price
Zimmer Biomet (NYSE:ZBH – Get Free Report) had its target price lifted by analysts at Truist Financial from $117.00 to...
FOX (NASDAQ:FOX) Sets New 12-Month High – Should You Buy?
Fox Co. (NASDAQ:FOX – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock...
PagSeguro Digital (NYSE:PAGS) Hits New 52-Week Low – Time to Sell?
PagSeguro Digital Ltd. (NYSE:PAGS – Get Free Report)’s share price reached a new 52-week low on Wednesday . The stock...
Rexford Industrial Realty (NYSE:REXR) Reaches New 12-Month Low – Time to Sell?
Shares of Rexford Industrial Realty, Inc. (NYSE:REXR – Get Free Report) reached a new 52-week low on Wednesday . The...